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recurred and previously radiated digestive tumors. This 
treatment offers adequate locoregional control with 
acceptable range of complications. 
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Purpose or Objective: To study normal skin acute toxicity in 
Non-Melanoma Skin Cancer (NMSC) patients treated with High 
Dose Rate (HDR) Plesiotherapy and very high viscosity 
addition silicone (VHVAS) rubber custom-made molds. VHVAS 
rubber features excellent mechanical and physical properties 
which benefit the stability and reproducibility of the implant. 
On the other hand, the high electron density relative to 
water of these materials will increase the scatter production, 
which may be relevant at the mold-skin interface. 
 
Material and Methods: Our standard applicators are 
polymerized VHVAS molds with catheters embedded. This 
VHVAS model features 99.5% recovery factor after 
compression and maximum 0.20% linear dimensional 
variations. Dosimetric properties of this VHVAS have been 
characterized by our Group elsewhere. Silicone attenuation 
relative to water is <5% up to 3 mm thickness. Maximum 
scatter relative to water measured at the mold interface is 
<14%. Treatment is delivered with a Ir-192 based VARIAN MS 
Gammamed+ HDR unit. All treatments are 3D simulated. A 
sample of 15 Patients with 21 lesions (8 basal cell 
carcinomas, 13 squamous cell carcinomas) representing all 
treated locations were considered. Average age is 83.1 years 
[96-58], 47% without any concomitant diseases and life 
expectancy >5 years. Median lesion area is 5.4 cm2 [1.0-
46.6], treatment depth is 4.0 mm [2-15] and microscopic 
disease margin is 4 mm [2-5]. Standard fractionation is 5.5 
Gy/fr, 10-12 fr, twice a week. Acute toxicity was 
retrospectively assessed following the RTOG criteria. 
 
Results: DVH analysis showed high dose areas having: 
D1cc=8.5 Gy/fr [5.4-14.4], D0.5cc= 9.0 Gy/fr [5.4-16.3], 
D0.1cc= 10.3 Gy/fr [6.2-22.9]. All patients presented 
radiodermatitis 1 month after treatment (G2: 89%, G3: 11%). 
32% presented radiodermatitis at 3 months (G1: 26%, G2: 6%) 
and only one patient presented radiodermatitis G1 at 6 
months. Toxicity score correlation to CTV volume, treatment 
depth, BED prescribed dose, D1cc, D0.5cc and D0,1cc had no 
statistical significance (p>0.05). Treated area was found to 
be predictive of radiodermatitis persistence at 3 months 
after treatment (p=0.036). Lesions located in the legs showed 
longer recovery time from radiodermatitis than other 
locations (4 months vs 1.8 months average). 
 
Conclusion: The use of these VHVAS moulds was well-
tolerated by all patients. Our treatments yield similar results 
to other groups with similar treatment schemes in terms of 
acute toxicity. We can conclude that VHVAS custom made 
molds have a good safety profile. 
 
EP-2016  
A method to transform 2D LDR brachytherapy plans into 
contemporary 3D PDR dose distributions 
E. Rodenburg
1Academic Medical Center / University of Amsterdam, 
Department of Radiation Oncology, Amsterdam, The 
Netherlands 
1, J. Wilkes1, J. Wiersma1, R. Ordoñez 
Marmolejo1, R. Dávila Fajardo1, A. Bel1, B. Pieters1 
 
Purpose or Objective: Formerly in the 2D Low-Dose Rate 
(LDR) era no information about Dose-Volume Histogram (DVH) 
parameters of organs at risk (OARs) was available in 
brachytherapy plans. To enable research on late dose effects 
for children treated with Pulsed-Dose Rate (PDR), 3D dose 
distributions and DVH parameters are required. In this study 
a method was developed to enable calculation of DVH 
parameters. 
 
Material and Methods: Before 2001 pediatric head and neck 
(H&N) patients received LDR brachytherapy as a part of their 
treatment. Of 16 LDR plans (1989-2001) only hard-copy CT 
data, orthogonal x-ray images of the implant and 
documented 2D dose information were available. The 
documented 2D dose information consisted of source 
strength, catheter numbering, catheter loading, and 
treatment time. The hard-copy CT data was digitized, 
transferred to DICOM format and imported in Oncentra 
Brachy (Elekta, v4.3). The visible OARs were delineated and 
used catheters were reconstructed. The Ir192-LDR line 
sources from the original 2D plans were simulated by loading 
the reconstructed catheters with Ir192-PDR source tracks of 
the same length as the LDR sources, with a step size of 
2.5mm. Simulation of a line source dosimetry was necessary 
because the planning system did not support LDR planning. 
All PDR source dwell times were made equal, but scaled to 
the documented 2D dose distribution to obtain the 3D dose 
distribution at time of treatment. Scaling was performed at a 
2D LDR isodose level below 30% of the prescribed dose in a 
plane where the documented 2D dose distribution and 
transformed 3D dose distribution geometrically match. 
Scaling below 30% is done to avoid effects due to the non-
uniform isodose distribution very close to a stepping PDR 
source. To check the reliability of the method the Total 
Reference Air Kerma (TRAK) for both 2D LDR and 3D PDR 
plans were determined and compared. The difference was 
tested with the Wilcoxon Signed Rank Test for paired 
variables. To illustrate the applicability of the method the 
maximum dose, defined as the D0.1cm3, on e.g. chiasm was 
determined. 
 
Results: Of 16 LDR plans 2D data were transformed into 3D 
dose distributions. OARs and DVH parameters of chiasm were 
determined. The mean 2D TRAK was 0.95cGy/1m (IQR 0.89). 
The mean 3D TRAK was 0.89cGy/1m (IQR 0.74). The mean 
difference of 2D TRAK and 3D TRAK was statistically not-
significantly different from 0 (P=0.45). For 7 patients the CT 
data incorporated the chiasm area. The mean chiasm 
maximum dose was 233.6cGy (range 4.6-399.2) using the 
described method. 
 
Conclusion: With the described method it was possible to 
transform 2D LDR brachytherapy plans into a 3D dose 
distribution. This method shows the possibility to use 
information from 2D LDR brachytherapy plans in scientific 
studies in which 3D dose information is needed. 
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Purpose or Objective: To evaluate outcomes and toxicities 
after high dose-rate (HDR) endoluminal brachytherapy for the 
treatment of esophageal cancer patients. 
 
Material and Methods: We analyzed the patient records of 36 
patients treated with high dose-rate endoluminal 
brachytherapy for histologically confirmed esophageal 
cancer. Brachytherapy was either applied as a boost 
treatment for definitive radiotherapy and radio-
chemotherapy regimens or as a salvage treatment for 
recurrent tumors. Single radiation doses between 4 and 6 Gy 
were delivered to the endoscopically visible tumor including 
2 cm margins in 2 to 4 sessions. Recurrence-free and overall 
